Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | HPGD | P15428 | 2/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.54 |
| ▸ | TUBB | P07437 | 5/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albendazole SCHEMBL7969988 | 1.00 | LMNA (0.83) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL44682 | 1.00 | LMNA (0.83) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28958723 | 0.99 | LMNA (0.81) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28582887 | 0.99 | LMNA (0.81) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL23038783 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL15553526 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL23038781 | 0.94 | LMNA (0.74) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL5944379 | 0.94 | LMNA (0.73) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28470926 | 0.94 | LMNA (0.73) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 | |
| Albendazole SCHEMBL28325579 | 0.93 | LMNA (0.72) | LMNACYP1A2MAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060043-B1 | PESTICIDAL COMPOSITIONS AND RELATED METHODS | CORTEVA AGRISCIENCE LLC (US) | 2025-11-26 | — | — | EP | claimed |
| EP-3578542-B1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-11-12 | — | — | EP | claimed |
| US-12465623-B2 | Use of parasites and extracellular vesicles obtained from parasites in cancer treatment | YEDITEPE UNIVERSITESI (TR) | 2025-11-11 | — | — | US | claimed |
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-3965808-B1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | UNIV YEDITEPE (TR) | 2025-09-03 | — | — | EP | claimed |
| EP-3578543-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-08-20 | — | — | EP | claimed |
| EP-3578541-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-05-28 | — | — | EP | claimed |
| EP-3923988-B1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | SOM INNOVATION BIOTECH S A (ES) | 2025-04-30 | — | — | EP | claimed |
| EP-3180349-B1 | LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF | UNIV MONASH (AU) | 2025-03-12 | — | — | EP | claimed |
| EP-4140504-B1 | MICELLE MADE FROM BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | BIOMETRIX TECH INC (KR) | 2025-01-15 | — | — | EP | claimed |
| EP-3843705-B1 | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS WITH LITTLE OR NO STABILIZING AGENTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-29 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| EP-3614845-B1 | FUNGICIDAL COMBINATIONS | UPL LTD (IN) | 2023-11-01 | — | — | EP | claimed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3062790-B1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | PITNEY PHARMACEUTICALS PTY LTD (AU) | 2023-03-08 | — | — | EP | claimed |
| US-20220226393-A1 | USE OF PARASITES AND EXTRACELLULAR VESICLES OBTAINED FROM PARASITES IN CANCER TREATMENT | YEDITEPE UNIVERSITESI (TR) | 2022-07-21 | — | — | US | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022077087-A1 | MICROSUSPENSION AGAINST PARASITES AND METHOD FOR OBTAINING SAME | IPANEMA INDUSTRIA DE PRODUTOS VETERINARIOS LTDA (BR) | 2022-04-21 | — | — | WO | claimed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295787-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | SI, PIM1, PIM3 | LMNA 766/4885CYP1A2 389/4885MAPK1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.